TNFRSF8 and diffuse large B-cell lymphoma: It is also currently being investigated in the frontline setting for the treatment of Hodgkin's lymphoma (ECHELON-1 [16]) and CD30+ peripheral T-cell lymphoma (ECHELON-2 [18]) and as salvage therapy for relapsed CD30+ DLBCL where ifosfamide, carboplatin, and etoposide (ICE) are given following BV if disease persists after 2 cycles of BV (Clinical trial no. NCT01508312) [29].